Streptococcus agalactiae
A test for detecting Streptococcus agalactiae DNA in human biomaterial and its bacterial cultures, in catheter flushes and endotracheal tubes using PCR.
Category «Other infections»
Streptococcus agalactiae
Streptococcus agalactiae (group B Streptococcus) is a Gram-positive facultative anaerobe belonging to the Streptococcaceae family. In humans, S. agalactiae colonizes the gastrointestinal and urogenital tracts, as well as the oral and nasal cavities. Most infected adults do not develop symptoms, thus becoming healthy carriers of the infection. However, infectious processes may occur in pregnant women, newborns, the elderly, and in patients with immunodeficiencies.
Streptococcus agalactiae possesses numerous pathogenicity factors that ensure its survival and dissemination within the host. Capsular polysaccharides protect bacteria from phagocytosis, while adhesins and exotoxins promote attachment to cells and induce an inflammatory response, which explains the ability of S. agalactiae to cause infections of varying severity.
In adult patients, S. agalactiae can cause a number of serious medical conditions, including osteomyelitis, necrotizing fasciitis, myositis, sepsis, pneumonia, arthritis, meningitis, endocarditis, and urogenital tract infections.
S. agalactiae poses the greatest threat to newborn infants. S. agalactiae is a frequent cause of severe infections and illnesses in the early neonatal period, including sepsis, meningitis, pneumonia, osteomyelitis, pyelonephritis and arthritis. Infection often occurs during labor, especially during vaginal delivery. The risk of disease in a full-term infant is 1-2%. In premature infants, the risk is up to 20%, and at less than 28 weeks' gestation it is nearly 100%.
Given the high likelihood of infection in newborns and the risk of postpartum complications in the parturient, the CDC (Center for Disease Control and Prevention) recommends screening pregnant women for S. agalactiae at 35-37 weeks of gestation and, if risk factors are present, at any other stages of pregnancy.
Screening for S. agalactiae carriage and subsequent therapy during pregnancy can help detect bacterial colonization of a woman's birth canal and reduce the risk of intrauterine infection in newborn.
Testing/evaluating pregnant women and women in labor for ______ in the absence of previous screening is necessary for antibiotic prophylaxis in labor.
Indications for testing
-
Pregnancy -
Planned delivery (in the absence of previous screening) -
Preterm labor -
Clinical symptoms of intrauterine infections -
Sepsis -
Infectious processes of various localizations in the elderly and immunocompromised patients -
Urinary tract infections -
Obstetric and perinatal complications
Streptococcus agalactiae
The Streptococcus agalactiae Real-Time PCR Detection Kit is in vitro DNA test, which is intended for the specific identification of Streptococcus agalactiae in human biological samples.
Sample: blood, phlegm, urine, scrapes from respiratory tract, urogenital and gastrointestinal tracts, faeces or meconium, bioptates, cerebrospinal fluid, washings from catheters and endotracheal tubes and bacterial cultures
READ MORE
Ask questions
Please note that the specialists of the DNA Technology company provide consultations exclusively to medical specialists on the application and research features. Requests related to the appointment, delivery, or interpretation of tests are not considered. For relevant information, we recommend contacting the laboratory directly.